AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05793944 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control text messaging
Description: Control arm participants will receive weekly text messages with accurate, general-interest information about pregnancy and about progress of the trial. Content is not geared to decision-making during pregnancy that may affect health outcomes.
Study NCT06413641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation
Description: As described before
Study NCT06413641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualization of CTA images
Description: As described before
Study NCT05168150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Experimental Group - Intelligent Continuous Expertise Monitoring System group
Description: During each of the practice task they will receive real-time auditory feedback instructed by the intelligent system. After each attempt, a student takes a 5-minute break. They will be shown the errors they made during the task regarding five performance metrics. After seeing each error, they will be shown video demonstration to learn how to expertly perform at each performance metrics. On their 6th attempt they will perform on the realistic scenario without any feedback given.
Study NCT05168150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group In-person expert-mediated instruction group
Description: During each of the practice task, students will receive verbal feedback from the expert instructor present in the room. After each task, experts will summarize their performance and outline the errors the student made. Based on the student's performance, expert will demonstrate how to expertly perform the task in the simulation, and how to improve their performance in the next attempt. Students will perform the 6th attempt on the realistic scenario without any instruction given.
Study NCT04790201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship Bench Delivered by Professional Counselor
Description: Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.
Study NCT04790201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship Bench Delivered by Lay Counselor
Description: Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.
Study NCT04790201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.
Study NCT04428944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)
Description: Standard PVI
Study NCT04428944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)
Description: Standard PVI + Ablation of drivers in LA and RA
Study NCT04428944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)
Description: Standard PVI + Electrical isolation of the posterior wall of the left atrium
Study NCT05075772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080
Study NCT05265520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: His-CRT implantation
Description: The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
Study NCT05265520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BIV-CRT implantation
Description: Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
Study NCT05167760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraclonidine
Description: 1-2 drops per eye every 8 hours for 2 weeks
Study NCT04837170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional therapy + S (+)-Ketamine
Description: Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
Study NCT04837170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Study NCT05517720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aria Trio complete Facial System
Description: Renew Serum, Brighten Serum, and Refine Serum.
Study NCT06043570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Monitoring arm
Description: Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
Study NCT05428982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Modified Trendelenburg position
Description: Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
Study NCT04647487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.
Study NCT06052215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Information Cards Education
Description: Providing family planning education to women through online information cards
Study NCT05911282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study.
Study NCT05911282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lemon juice
Description: The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study.
Study NCT05381337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sideburns mini incision
Description: The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
Study NCT05381337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronal scalp incision
Description: Coronal scalp incisions were used as control group.
Study NCT05783882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolgolimab
Description: 250 mg Q3W
Study NCT06206954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHealthPath Tool
Description: Tailored, brief online tool to help patients learn about weight treatment options
Study NCT06206954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyHealthPath Guide
Description: Informational material to help patients learn about weight treatment options
Study NCT00997542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Study NCT00997542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04457895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational yoga program
Description: Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)
Study NCT04457895 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: no yoga session at home and no yoga -therapeutic educatuion session
Study NCT05918081 — intervention group
Intervention type: OTHER
Intervention: Multi-Stage 20 m Shuttle Run Test
Description: The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer.
Study NCT04781231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MusicCare® device
Description: The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
Study NCT04781231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device with quiet recorded music
Description: An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
Study NCT04781231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual management of anxiety
Description: No specific intervention
Study NCT06253858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Placement with Solopass System
Description: This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
Study NCT05903443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ancillary tests
Description: electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
Study NCT05220930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot bath for heel warming
Description: In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
Study NCT05220930 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ineffective heel warming with thermofor
Description: Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serum Autotaxin
Description: Marker
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Autotaxin
Description: Marker
Study NCT06574425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long-term, high blood flow hemoadsorption therapy
Description: Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group
Study NCT05630300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PMC Sure Status COVID-19 Antigen Test
Description: COVID-19 professional use kit in out-patient departments
Study NCT05630300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acon Flowflex COVID-19 Antigen Home Test
Description: COVID-19 self-test kits
Study NCT06283927 — intervention group
Intervention type: PROCEDURE
Intervention: Re-resection
Description: Resection of the recurrent tumor
Study NCT06283927 — intervention group
Intervention type: DRUG
Intervention: Temozolomide
Description: Re-challenge Temozolomide chemotherapy
Study NCT06283927 — intervention group
Intervention type: DRUG
Intervention: Lomustine
Description: Second line chemotherapy with Lomustine
Study NCT06283927 — intervention group
Intervention type: RADIATION
Intervention: Re-irradiation
Description: Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
Study NCT06283927 — intervention group
Intervention type: PROCEDURE
Intervention: Experimental therapy
Description: Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
Study NCT06283927 — intervention group
Intervention type: OTHER
Intervention: Best supportive care
Description: Best supportive care, focused on alleviating symptoms
Study NCT06325930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-HU6
Description: \[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
Study NCT04328194 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest x-ray
Description: chest x- ray will be done for the study group
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast ultrasound or mammography
Description: Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histopathological examination of breast mass specimens
Description: by True cut or fine needle aspiration cytology
Study NCT04328194 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging ( MRI) and Bone scan
Description: will be done for the study group
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral haemogram
Description: blood sample will be taken from the patients
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal and liver functions
Description: to exclude any other morbidity
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prothrombin time and concentration
Description: blood sample will be taken from the patients
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cancer Antigen 15-3 (CA15-3).
Description: will be done for the 2 groups
Study NCT04328194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cancer Antigen 15-3 (CA15-3).
Description: will be done for the 2 groups
Study NCT04328194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Full medical history
Description: full medical history will be taken from all patients
Study NCT04328194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full medical history
Description: full medical history will be taken from all patients
Study NCT04328194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Full clinical examination
Description: full clinical examination will be done for the patients
Study NCT04328194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full clinical examination
Description: full clinical examination will be done for the patients
Study NCT05901961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Whitfield solution
Description: The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study NCT06438146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration
Study NCT04720261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Caplacizumab
Description: Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
Study NCT06245551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
Study NCT06245551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Description: Placebo aerosol for inhalation, single dose (given as 2 actuations)
Study NCT05901961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc oxide nanoparticles solution
Description: The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study NCT04898621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 75g fructose solution
Description: Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
Study NCT04898621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 150g fructose solution
Description: Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
Study NCT06134531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR001
Description: Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle
Study NCT05901961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Whitfield and Zinc oxide nanoparticles solution
Description: The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study NCT05436288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
Description: KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
Study NCT05817604 — intervention group
Intervention type: RADIATION
Intervention: SBRT
Description: Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme.~Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme.
Study NCT04616521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
Study NCT05985980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Treadmill Test (ETT)
Description: The study population consists of premenopausal women who applied to the outpatient clinic with chest pain. ETT is ordered as a routine diagnostic workup. Two ETTs are performed on each participant. The early follicular phase ETT is planned on the 3rd day of menstrual bleeding, while the menstrual bleeding continues. The late follicular phase ETT is planned on the 3rd day after the menstrual bleeding ends. Hormone levels are measured before each ETT to ascertain the phase of the menstrual cycle.
Study NCT05573282 — intervention group
Intervention type: OTHER
Intervention: Regorafenib combine with ICIs
Description: Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
Study NCT03645447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Taste test
Description: A pseudo-randomised series of taste solutions are presented to the participant for identification as sugar or water, in order to establish their taste threshold.